EE200300172A - Antigeenne kompositsioon ja adjuvantsegu - Google Patents

Antigeenne kompositsioon ja adjuvantsegu

Info

Publication number
EE200300172A
EE200300172A EEP200300172A EEP200300172A EE200300172A EE 200300172 A EE200300172 A EE 200300172A EE P200300172 A EEP200300172 A EE P200300172A EE P200300172 A EEP200300172 A EE P200300172A EE 200300172 A EE200300172 A EE 200300172A
Authority
EE
Estonia
Prior art keywords
antigenic composition
adjuvant mixture
adjuvant
mixture
antigenic
Prior art date
Application number
EEP200300172A
Other languages
English (en)
Estonian (et)
Inventor
Hagen Michael
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of EE200300172A publication Critical patent/EE200300172A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200300172A 2000-11-10 2001-11-08 Antigeenne kompositsioon ja adjuvantsegu EE200300172A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24710000P 2000-11-10 2000-11-10
US33034501P 2001-10-18 2001-10-18
PCT/US2001/046943 WO2002038177A2 (en) 2000-11-10 2001-11-08 Adjuvant combination formulations

Publications (1)

Publication Number Publication Date
EE200300172A true EE200300172A (et) 2003-06-16

Family

ID=26938452

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300172A EE200300172A (et) 2000-11-10 2001-11-08 Antigeenne kompositsioon ja adjuvantsegu

Country Status (26)

Country Link
US (2) US20040156820A1 (ko)
EP (1) EP1343527A2 (ko)
JP (2) JP2004523483A (ko)
KR (1) KR100863368B1 (ko)
CN (1) CN1533285A (ko)
AU (2) AU2597202A (ko)
BG (1) BG107798A (ko)
BR (1) BR0115271A (ko)
CA (1) CA2429000A1 (ko)
CZ (1) CZ20031225A3 (ko)
EA (1) EA004744B1 (ko)
EE (1) EE200300172A (ko)
EG (1) EG24378A (ko)
GE (1) GEP20074077B (ko)
HR (1) HRP20030355A2 (ko)
HU (1) HUP0600589A2 (ko)
IL (1) IL155690A0 (ko)
IS (1) IS6809A (ko)
MX (1) MXPA03004071A (ko)
NO (1) NO20032086L (ko)
NZ (1) NZ525887A (ko)
PE (1) PE20020530A1 (ko)
PL (1) PL366031A1 (ko)
SK (1) SK5482003A3 (ko)
TW (1) TWI239848B (ko)
WO (1) WO2002038177A2 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
PT2336147E (pt) 2003-12-17 2014-07-16 Janssen Alzheimer Immunotherap Conjugados transportadores de péptidos beta imunogénicos e seus processos de produção
WO2006047670A2 (en) * 2004-10-26 2006-05-04 Wyeth Methods for assessing antibodies to neurodegenerative disease-associated antigens
KR100878585B1 (ko) 2006-06-16 2009-01-15 국립암센터 글루코사민, 글루코사민 유도체 또는 이들의 염을 포함하는항암감작제
US9498522B2 (en) * 2008-08-07 2016-11-22 Mercia Pharma Inc. Immunotherapeutic compositions for the treatment of alzheimer'S disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5939074A (en) 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5019387A (en) 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
US5993819A (en) 1987-09-08 1999-11-30 Duke University Synthetic vaccine for protection against human immunodeficiency virus infection
US5013548A (en) * 1987-09-08 1991-05-07 Duke University Production of antibodies to HIV
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
CA1340506C (en) * 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP2893653B2 (ja) 1988-11-10 1999-05-24 ジェネティックス・インスティテュート・インコーポレイテッド ナチュラルキラー細胞刺激因子
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
ATE190226T1 (de) 1991-12-02 2000-03-15 Univ Texas Zusammensetzungen zum auslösen cytotoxischer t- lymphozyten gegen viren
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
US5679356A (en) * 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5571515A (en) * 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
US5679256A (en) * 1994-06-20 1997-10-21 Rose; Jane Anne In-situ groundwater clean-up and radionuclide disposal method
EP0784486B1 (en) * 1994-10-05 2006-04-05 Vanderbilt University Interleukin-12 as an adjuvant for paramyxoviridae vaccines
US5939075A (en) * 1994-11-04 1999-08-17 The United States Of America As Represented By The Secretary Of The Army Mutants of Brucella melitensis
US5955087A (en) * 1995-02-24 1999-09-21 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
US6613337B1 (en) * 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
JPH09124697A (ja) * 1995-11-01 1997-05-13 Toagosei Co Ltd ペプチド及びモノクローナル抗体
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
DE69735856T2 (de) * 1996-05-31 2006-11-16 National University Of Ireland Maynooth, Maynooth Il-12 als adjuvanz für bordetella pertussis impfstoffe
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
US6797276B1 (en) * 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6350456B1 (en) * 1997-03-13 2002-02-26 Corixa Corporation Compositions and methods for the prevention and treatment of M. tuberculosis infection
US6113918A (en) * 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9712347D0 (en) * 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2002502884A (ja) * 1998-02-12 2002-01-29 アメリカン・サイアナミド・カンパニー インターロイキン−１２および単純ヘルペスウイルス抗原を含んでなるワクチン
CA2323929C (en) 1998-04-03 2004-03-09 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
EA006233B1 (ru) 1999-05-13 2005-10-27 Уайт Холдингз Корпорейшн Комбинированные адъювантные композиции для усиления иммунного ответа у позвоночного животного
US7396535B2 (en) * 2003-04-25 2008-07-08 Ackerman Alan H Therapy for obsessive compulsive head banging

Also Published As

Publication number Publication date
JP2010001304A (ja) 2010-01-07
AU2597202A (en) 2002-05-21
NZ525887A (en) 2005-08-26
GEP20074077B (en) 2007-03-26
NO20032086L (no) 2003-07-07
NO20032086D0 (no) 2003-05-09
JP2004523483A (ja) 2004-08-05
IL155690A0 (en) 2003-11-23
IS6809A (is) 2003-05-07
TWI239848B (en) 2005-09-21
AU2002225972B2 (en) 2006-06-29
WO2002038177A2 (en) 2002-05-16
BG107798A (en) 2004-07-30
US20070025959A1 (en) 2007-02-01
WO2002038177A3 (en) 2003-01-16
BR0115271A (pt) 2005-12-13
EP1343527A2 (en) 2003-09-17
EA004744B1 (ru) 2004-08-26
KR100863368B1 (ko) 2008-10-13
PE20020530A1 (es) 2002-06-18
PL366031A1 (en) 2005-01-24
KR20040043098A (ko) 2004-05-22
HUP0600589A2 (en) 2006-11-28
MXPA03004071A (es) 2003-09-04
EG24378A (en) 2009-03-26
HRP20030355A2 (en) 2005-04-30
SK5482003A3 (en) 2004-03-02
CN1533285A (zh) 2004-09-29
US20040156820A1 (en) 2004-08-12
CZ20031225A3 (cs) 2003-10-15
CA2429000A1 (en) 2002-05-16
EA200300557A1 (ru) 2004-04-29

Similar Documents

Publication Publication Date Title
NO20026175L (no) Vaksinesammensetning
NO20004758L (no) Vaksinesammensetning
DK1390066T3 (da) Vaccinesammensætning
NO20004487D0 (no) Kombinerte vaksinesammensetninger
ATE490327T1 (de) Impfstoffzusammensetzung
HUP0302117A3 (en) Vaccine composition
EE200300151A (et) Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks
NO20031483D0 (no) Vaksine
GB0020089D0 (en) Vaccine Composition
DE60027029D1 (de) Kombinierte impfstoffzusammensetzungen
IL146904A0 (en) Gypsum compositions and related methods
NO20024172L (no) Vaksine
BR0115102B1 (pt) Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
PT1139764E (pt) Composicao adjuvante
DK1170337T3 (da) Farvemiddelblanding
DE60137637D1 (de) Magnetorheologische fettzusammensetzung
DK1265633T3 (da) Vaccineadjuvans
ID17860A (id) Komposisi vaksin
DE60116858D1 (de) Zusammensetzung
EE200300172A (et) Antigeenne kompositsioon ja adjuvantsegu
DE60104098D1 (de) Brennstoffzusammensetzung
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin
DE60139633D1 (de) Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
AU2001267541A1 (en) Vaccine composition
DE60140939D1 (de) Nd darin verwendete zusammensetzung